Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Nathan

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Cancer Research|September 10, 2009
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agentsYuval Shaked, Terence Tang, Jill Woloszynek, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Journal for Immunotherapy of Cancer|July 13, 2018
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)Paolo A Ascierto, James Brugarolas, Luigi Buonaguro, et al.
European Journal of Cancer (Oxford, England : 1990)|August 30, 2025
Uveal Melanoma UK national guidelines: 2023 updateThomas J Carter, Jack Broadfoot, Sarah E Coupland, et al.
The Cochrane Database of Systematic Reviews|July 2, 2019
Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanomaJacqueline Dinnes, Lavinia Ferrante di Ruffano, Yemisi Takwoingi, et al.
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Journal of Translational Medicine|January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
JMIR Cancer|April 25, 2025
Co-Designing Priority Components of an mHealth Intervention to Enhance Follow-Up Care in Young Adult Survivors of Childhood Cancer and Health Care Providers: Qualitative Descriptive StudySharon H J Hou, Brianna Henry, Rachelle Drummond, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Cancer Research|September 10, 2009
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agentsYuval Shaked, Terence Tang, Jill Woloszynek, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Journal for Immunotherapy of Cancer|July 13, 2018
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)Paolo A Ascierto, James Brugarolas, Luigi Buonaguro, et al.
European Journal of Cancer (Oxford, England : 1990)|August 30, 2025
Uveal Melanoma UK national guidelines: 2023 updateThomas J Carter, Jack Broadfoot, Sarah E Coupland, et al.
The Cochrane Database of Systematic Reviews|July 2, 2019
Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanomaJacqueline Dinnes, Lavinia Ferrante di Ruffano, Yemisi Takwoingi, et al.
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Journal of Translational Medicine|January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
JMIR Cancer|April 25, 2025
Co-Designing Priority Components of an mHealth Intervention to Enhance Follow-Up Care in Young Adult Survivors of Childhood Cancer and Health Care Providers: Qualitative Descriptive StudySharon H J Hou, Brianna Henry, Rachelle Drummond, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Pageof 13